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Background: To demonstrate how assessment of life expectancy and loss in expectation of life can be used to
address a wide range of research questions of public health interest pertaining to the prognosis of cancer patients.
Methods: We identified 135,092 cases of colon adenocarcinoma diagnosed during 1961–2011 from the
population-based Swedish Cancer Register. Flexible parametric survival models for relative survival were used
to estimate the life expectancy and the loss in expectation of life.
Results: The loss in expectation of life for males aged 55 at diagnosis was 13.5 years (95 % CI 13.2–13.8) in 1965 and 12.8
(12.4–13.3) in 2005. For males aged 85 the corresponding figures were 3.21 (3.15–3.28) and 2.10 (2.04–2.17). The pattern
was similar for females, but slightly greater loss in expectation of life. The loss in expectation of life is reduced
given survival up to a certain time point post diagnosis. Among patients diagnosed in 2011, 945 life years could
potentially be saved if the colon cancer survival among males could be brought to the same level as for females.
Conclusion: Assessment of loss in expectation of life facilitates the understanding of the impact of cancer, both
on individual and population level. Clear improvements in survival among colon cancer patients have led to a
gain in life expectancy, partly due to a general increase in survival from all causes.
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SwedenBackground
The most commonly reported measure of cancer patient
survival in population-based cancer studies is the 5-year
relative survival ratio (RSR) [1]. It is a useful measure
when comparing cancer survival over time or between
groups as it should not be affected by varying mortality
due to other causes. However, it is not easy to grasp
what the RSR means in terms of the life expectancy of
the patients. For example, increasing relative survival
suggests that cancer care has changed for the better over
time, although it does not necessarily lead to a decreas-
ing loss in expectation of life. The loss in expectation of
life of the patients, measured as the difference between
the expected remaining life in the absence of cancer and* Correspondence: therese.m-l.andersson@ki.se
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also depends on temporal changes in the overall life ex-
pectancy. Therefore, investigating the impact of changes
in survival in terms of loss in expectation of life should
provide additional insight into studies of cancer patient
survival and is potentially of greater interest for patients
and clinicians. Moreover, the loss in expectation of life is
also a measure of public health interest since it provides
a better understanding of the impact of cancer in the
population.
The loss in expectation of life can be quantified both
at the individual and population level. For example, how
many life years does a person of a particular age on aver-
age lose due to their cancer diagnosis (individual level),
and what is the total number of life-years lost in a par-
ticular population (population level)? However, these
measures are used very little in practice since estimation
generally requires extrapolation of survival as the studies
typically don’t follow all patients to the end of life. In atral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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life can be reliably estimated using flexible parametric
relative survival models [3], and we developed software
to enable the estimation [4].
For the purpose of the present study, we demonstrate
how estimation of loss in expectation of life can be used
to address a wide range of research questions of public
health interest pertaining to the survival and prognosis of
colon cancer patients. Using data from the population
based Swedish Cancer Register, the aim of the present
study was three-fold. Firstly, to examine how life expect-
ancy and loss of expectation of life for patients with colon
cancer has changed over calendar time and to estimate
the loss in expectation of life for recently diagnosed pa-
tients. Secondly, to estimate loss of expectation of life con-
ditional on survival to, for example, one and five year after
diagnosis, and thirdly to examine how many life-years can
potentially be saved at a population level if sex differences
in colon cancer survival could be eliminated.
Methods
Data
All incident cases of colon adenocarcinoma were identi-
fied in the nationwide population-based Swedish Cancer
Register during the years 1961–2011. The Swedish Can-
cer Register was established in 1958. Clinicians and pa-
thologists are independently required by law to notify
the register about all new cases of cancer, which contrib-
utes to the completeness of the Swedish Cancer Register
[5]. For the purpose of the present study, individuals
with multiple records of primary colon adenocarcinomas
were only included with their first recorded diagnosis.
We excluded diagnoses that were detected incidentally
at autopsy, individuals aged less than 20 at diagnosis or
if the date of diagnosis was recorded to be after the date
of death. All patients were followed-up until death, first
emigration after diagnosis, 31/12-2012 or 15 years after
diagnosis, whatever came first.
Introduction to the statistical methods and concepts
Relative survival is defined as the ratio of the observed
all-cause survival among cancer patients and the ex-
pected survival in a comparable group in the general
population. It has become the preferred measure of can-
cer patient survival in population-based studies as it cap-
tures mortality that is either directly or indirectly related
to the cancer without requiring information on cause of
death [1]. The advantage of relative survival over cause-
specific survival is that cause of death is not always avail-
able or reliable. Even if accurate information on cause of
death is available it is often difficult to determine
whether or not a death is due to the diagnosed cancer or
not. For example it may not be obvious how to classify
deaths that are secondary effects of treatment. Thelimitation of relative survival is that a comparable group
in the general population has to be defined to obtain the
expected survival. Population life tables are usually used,
stratified on age, calendar year and sex, and the cancer
patients are assumed to have the same expected survival
as the general population. This assumption is generally
feasible for colon cancer, but not for smoking-related
cancers such as lung cancer where the patients would
have a lower expected survival than the general popula-
tion. It is interpreted as the proportion of patients still
alive in the hypothetical scenario where cancer is the
only possible cause of death. The mortality analogue to
relative survival is excess mortality, defined as the differ-
ence between the observed all-cause mortality rate
among cancer patients and the expected mortality rate
in a comparable group in the general population.
The expectation of life from the date of cancer diagnosis
until death (due to any cause) gives an estimate of the aver-
age number of years cancer patients are expected to live
after they are diagnosed with cancer. The loss in expect-
ation of life due to cancer is the difference between the an-
ticipated expectation of life (in the absence of cancer), and
the expectation of life among the cancer patients [2]. The
anticipated expectation of life can be estimated from popu-
lation mortality tables. Estimation of life expectancy gener-
ally requires extrapolation of the survival function, due to
limited follow-up, since it requires all subjects to have died.
It has been shown that the extrapolation of the observed
survival function can be done reliably using flexible para-
metric survival models within a relative survival approach
[3]. Flexible parametric survival models are fitted on the log
cumulative hazard scale [4, 6, 7] and model the baseline
hazard directly via restricted cubic splines and thus obviate
the need to pre-specify a parametric distribution for the
survival function. In this framework, various assumptions
about the future excess mortality can be made, but since
the long-term excess mortality constitutes a relatively small
part of the all-cause mortality from around 6 or 7 years
after diagnosis, the extrapolation is not heavily dependent
on these assumptions.
Traditionally, cancer patient survival is estimated from
time of diagnosis. However, from a clinical perspective it is
also important to know how the survival changes as pa-
tients have survived several years after diagnosis. This is es-
timated by conditional survival probabilities. Similarly, the
loss in expectation of life can be estimated conditional on
surviving past a certain point after diagnosis, by estimating
life expectancy and loss in expectation of life based on ex-
trapolated conditional survival functions.
In studies where the purpose of the investigation is to
provide estimates of the survival experience for recently di-
agnosed patients, a period approach to estimation (as op-
posed to a cohort approach) has been suggested and
proven empirically superior [8, 9]. In a period analysis, only
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short term survival whereas patients diagnosed further in
the past still contribute to estimates of long term survival.
This set-up is made possible by pre-specifying a period win-
dow, and only person-time experienced within the period
window contributes to the analysis.Modeling and estimation
To examine temporal trends in life expectancy and loss of
expectation of life for patients with colon cancer a flexible
parametric survival model for relative survival was fitted.
The fitted model was used to extrapolate excess mortality
beyond follow-up to enable estimation of life expectancy.
Age at diagnosis, sex and year of diagnosis were included
as covariates, with two-way interactions between all covar-
iates and time-dependent effects. Age and year of diagno-
sis were modeled continuously and non-linearly using
restricted cubic splines, and the results are presented for
selected ages and calendar years.
To obtain estimates for recently diagnosed patients, from
whom there is limited follow-up information, a period ana-
lysis was carried out with the period window set to 1/1-
2007–31/12-2012, and a flexible parametric model was
again fitted including the effects of age and sex.
Expected mortality rates, by age, sex and calendar year,
were available up until 2011 and extrapolations of expected
survival were based on population mortality projections
from Statistics Sweden [10], estimated using the Lee-Carter
method [11].
In order to quantify the impact of sex differences in sur-
vival, we applied the female cancer mortality rates to
males (but keeping the male background mortality rates)
to estimate what the loss in expectation of life for males
would be if males had the same cancer patient mortality
as females. This measure was used to calculate the total
number of life years that would potentially be gained in
the Swedish population if colon cancer survival among
males could be brought to the same level as for females.
In these calculations the total amount of life years lost for
all patients in 2011 were contrasted to the corresponding
total number of life years lost if males were given the fe-
male cancer mortality rates (as predicted from the model
using period analysis).
All analyses were performed using Stata 12 (Statacorp,
College Station, TX, USA). An extended description of
the modelling assumptions and estimation is provided in
Additional file 1. The study was approved by the Institu-
tional Review Board at Karolinska Institutet.Results
Descriptive statistics
Descriptive statistics for the 135,092 patients included in
the study are presented in Table 1. The most common agegroup at diagnosis was 70–79 years (36 % of the patients).
There were more females than males (52 vs. 48 %) and the
annual number of patients diagnosed increased with cal-
endar time. The total follow-up time was 635,449 person-
years and 100,208 patients died during follow-up.Temporal trends in life expectancy and loss of
expectation of life
Table 2 shows the estimated 5-year RSR, the loss in expect-
ation of life in years and the proportion of expected life lost,
for males and females of selected ages and calendar years.
The 5-year RSR decreased with increasing age for earlier
years (e.g. 40.6 % (95 % CI 39.3–41.9) for males in 1965
aged 55 and 24.8 % (23.2–26.5) for males aged 85), but is
fairly constant over age in 2005 (e.g. 61.5 % (60.5–62.6) for
a males aged 55 and 59.8 % (58.5–61.1), for males aged 85).
There was a clear increase in 5-year RSR over calendar
time, and females in general had a higher 5-year RSR than
males for all ages and calendar years.
Figure 1 shows temporal trends in life expectancy
from diagnosis for colon cancer patients and for a com-
parable disease-free general population. The difference
between these two curves gives the loss in expectation
of life. While the life expectancy for the colon cancer pa-
tients increased over calendar time, this increase mimics
to a large extent the increase observed in the general
population, and therefore the impact on the loss in ex-
pectation of life is modest (Table 2, Fig. 2). For example,
for males aged 55 at diagnosis the loss in expectation of
life was 13.5 years (95 % CI 13.2–13.8) in 1965 and 12.8
(12.4–13.3) in 2005. Female colon cancer patients have a
better life expectancy than males, but since females in
the general population have even higher life expectancy
than males, the loss in expectation of life was greater
among female patients.
There were pronounced age variations in life expect-
ancy for cancer patients, with younger patients surviving
longer. The loss in expectation of life decreased with
age, since younger patients have a longer life expectancy
in general. As an example, in 2005 males aged 85 lost on
average 2.10 years, 95 % CI 2.04–2.17, compared to
12.8 years for males aged 55.Conditional loss in expectation of life
The loss in expectation of life decreased with follow-up
time (Fig. 3), especially during the first few years post
diagnosis. For female patients diagnosed in 2000 who
had survived 5 years, the loss in expectation of life was
3.17 years (95 % CI 2.67–3.67) if diagnosed at age 55.
For those diagnosed at age 65, 75 or 85 the corresponding
conditional loss in expectation of life was 2.05 (1.80–2.29),
0.85 (0.74–0.97) and 0.06 (0.01–0.11) years respectively.
After 8–10 years the life expectancy of the cancer patients
Table 1 Descriptive statistics for colon cancer patients diagnosed in Sweden during 1961–2011. N= number of diagnoses, d = number of deaths during follow-upa, % d = percentage
dying during follow-upa
1961–1971 1972–1981 1982–1991 1992–2001 2002–2011 Total
N (%) d % d N D % d N D % d N D % d N D % d N d % d
Age
<50 1498 (7.3) 947 63.2 1180 (5.2) 716 60.7 1162 (4.4) 639 55.0 1282 (4.3) 632 49.3 1476 (4.2) 509 34.5 6598 (4.9) 3443 52.2
50–59 2800 (13.7) 1929 68.9 2667 (11.7) 1793 67.2 2480 (9.3) 1535 61.9 2905 (9.7) 1604 55.2 3280 (9.2) 1219 37.2 14,132 (10.5) 8080 57.2
60–69 5451 (26.7) 4481 82.2 5897 (26.0) 4567 77.5 6477 (24.4) 4665 72.0 6234 (20.9) 4059 65.1 8083 (22.8) 3113 38.5 32,142 (23.8) 20,885 65.0
70–79 6939 (34.0) 6506 93.8 8271 (36.4) 7557 91.4 10,015 (37.7) 8885 88.7 11,043 (36.9) 9130 82.7 12,224 (34.5) 5971 48.9 48,492 (35.9) 38,049 78.5
80+ 3731 (18.3) 3684 98.7 4697 (20.7) 4634 98.7 6439 (24.2) 6313 98.0 8440 (28.2) 8156 96.6 10,421 (29.4) 6964 66.8 33,728 (25.0) 29,751 88.2
Males 10,014 (49.0) 8819 88.1 10,803 (47.6) 9426 87.3 12,507 (47.1) 10,712 85.7 14,451 (48.3) 11,712 81.1 17,435 (48.8) 9058 52.0 65,210 (48.3) 49,727 76.3
Females 10,405 (51.0) 8728 83.9 11,909 (52.4) 9841 82.6 14,066 (52.9) 11,325 80.5 15,453 (51.7) 11,869 76.8 18,049 (51.2) 8718 48.3 69,882 (51.7) 50,481 72.2
Total 20,419 (15.1) 17,547 85.9 22,712 (16.8) 19,267 84.8 26,573 (19.7) 22,037 82.9 29,904 (22.1) 23,581 78.9 35,484 (26.3) 17,776 50.1 135,092 (100) 100,208 74.2












Table 2 5-year relative survival (5y RS), loss in expectation of life (LEL) and proportion of expected life lost (PELL) for selected ages,
together with 95 % confidence intervals, for colon cancer patients diagnosed in Sweden during 1961–2011
Age 55 Age 65 Age 75 Age 85
Males Females Males Females Males Females Males Females
1965 5y RS (%) 40.6 41.9 36.5 38.2 31.3 33.3 24.8 27.0
(39.3; 41.9) (40.7; 43.2) (35.5; 37.8) (37.2; 39.2) (30.2; 32.5) (32.2; 34.4) (23.2; 26.5) (25.4; 28.6)
LEL (years) 13.5 16.1 8.85 10.8 5.31 6.16 2.95 3.21
(13.2; 13.8) (15.8; 16.5) (8.70; 9.00) (10.6; 11.0) (5.22; 5.40) (6.06; 6.27) (2.89; 3.01) (3.15; 3.28)
PELL (%) 60.9 59.6 62.8 61.3 64.5 62.9 68.8 67.3
(59.6; 62.3) (58.2; 60.9) (61.8; 63.9) (60.2; 62.4) (63.4; 65.5) (61.8; 63.9) (67.4; 70.2) (65.9; 68.7)
1975 5y RS (%) 44.3 46.0 41.5 43.4 37.4 39.7 31.9 34.5
(43.2; 45.4) (44.9; 47.0) (40.6; 42.3) (42.6; 44.3) (36.5; 38.4) (38.8; 40.7) (30.4; 33.3) (33.1; 35.9)
LEL (years) 13.2 15.5 8.59 10.6 4.87 6.07 2.70 3.17
(12.9; 13.4) (15.2; 15.9) (8.46; 8.72) (10.5; 10.8) (4.80; 4.95) (5.98; 6.17) (2.64; 2.75) (3.11; 3.23)
PELL (%) 57.3 55.4 58.3 56.4 58.1 56.7 60.5 59.1
(56.2; 58.5) (54.2; 56.6) (57.4; 59.1) (55.5; 57.3) (57.3; 59.0) (55.8; 57.6) (59.3; 61.7) (57.9; 60.3)
1985 5y RS (%) 51.3 53.2 49.7 51.8 47.0 49.5 42.6 45.5
(50.4; 52.3) (52.3; 54.1) (48.9; 50.5) (51.1; 52.6) (46.1; 47.8) (48.7; 50.2) (41.3; 44.0) (44.4; 46.7)
LEL (years) 12.9 14.4 7.99 9.56 4.45 5.54 2.23 2.70
(12.7; 13.2) (14.1; 14.8) (7.86; 8.11) (9.40; 9.72) (4.38; 4.52) (5.45; 5.63) (2.18; 2.27) (2.65; 2.76)
PELL (%) 51.3 48.7 50.9 48.6 49.3 47.7 48.7 47.6
(50.2; 52.4) (47.6; 49.8) (50.1; 51.7) (47.8; 49.4) (48.5; 50.1) (47.0; 48.5) (47.6; 49.7) (46.6; 48.6)
1995 5y RS (%) 56.5 58.5 56.0 58.3 54.5 57.1 51.5 54.5
(55.5; 57.5) (57.6; 59.4) (55.2; 56.7) (57.5; 59.0) (53.7; 55.3) (56.3; 57.8) (50.2; 52.7) (53.4; 55.6)
LEL (years) 13.0 13.7 8.23 9.24 4.20 5.07 1.97 2.40
(12.7; 13.3) (13.4; 14.1) (8.09; 8.38) (9.06; 9.42) (4.12; 4.27) (4.97; 5.16) (1.92; 2.02) (2.34; 2.46)
PELL (%) 47.8 44.6 46.6 43.6 43.1 41.2 40.2 39.1
(46.6; 48.9) (43.5; 45.8) (45.7; 47.4) (42.8; 44.5) (42.3; 43.9) (40.5; 42.0) (39.2; 41.2) (38.2; 40.1)
2005 5y RS (%) 61.5 63.6 62.0 64.3 61.5 64.1 59.8 62.7
(60.5; 62.6) (62.6; 64.6) (61.2; 62.8) (63.5; 65.1) (60.6; 62.4) (63.3; 64.9) (58.5; 61.1) (61.6; 63.9)
LEL (years) 12.8 13.0 8.14 8.59 4.27 4.82 1.76 2.10
(12.4; 13.3) (12.5; 13.5) (7.91; 8.38) (8.33; 8.86) (4.16; 4.38) (4.69; 4.96) (1.70; 1.81) (2.04; 2.17)
PELL (%) 44.2 40.6 42.2 38.7 38.3 35.7 33.5 32.3
(42.6; 45.9) (38.9; 42.3) (41.0; 43.4) (37.5; 39.9) (37.3; 39.2) (34.7; 36.7) (32.5; 34.6) (31.3; 33.2)
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was similar for males and across calendar years.
Number of life years gained if males had the relative
survival of females
The estimated total number of life years lost for the 3827
patients diagnosed in 2011 in Sweden was 23,480 years
(Table 3). If males would have had the same cancer mortal-
ity as females (but still the background mortality of males)
this would instead have been 22,535 years, giving a poten-
tial gain of 945 life years. Table 3 also shows the potential
gain in loss in expectation of life at the individual level.
Males aged 55 at diagnosis would on average live 0.93 yearslonger if they had the same cancer patient mortality as
females aged 55 at diagnosis, whereas this number is
0.13 years for 85 year old males.Discussion
Life expectancy and loss in expectation of life can be
used to address a wide range of research questions of
public health interest pertaining to the prognosis of
cancer patients. We have demonstrated this by investi-
gating life expectancy and loss in expectation of life
after a diagnosis of colon cancer, how this changes over














































































































1960 1970 1980 1990 2000 2010
Year of diagnosis
Females, Age 85
Life expectancy of general population
Life expectancy of cancer patients
Fig. 1 Temporal trends in life expectancy from diagnosis for colon cancer patients diagnosed in Sweden during 1961–2011
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females.
Improved patient survival for cancer of the colon has
been observed in Sweden and many other countries
[12–16], reflecting improvements in adjuvant treatments
as well as surgical techniques and peri-operative care
that have led to an increasing proportion of patients
safely operated on [17–19]. Of special note is that there
seem to be only modest changes in the loss in expect-
ation of life over time for colon cancer patients, since
the improvements in the life expectancy in this patient
group to a large extent have mimicked the improvement
in life expectancy in the Swedish population. Whilst age
is an important predictor of prognosis for many types of
cancer, the 5-year RSR for colon cancer in Sweden is
now very similar across age groups [16]. However, sinceyoung individuals have a longer life expectancy, a cancer
diagnosis has a larger impact on loss in expectation of
life. Thus, with regard to prognosis as a function of age,
assessment of loss in expectation of life can provide a
complement to e.g. the 5-year RSR since it gives more
weight to young patients who have more years to lose.
Since cancer patient mortality changes with time since
diagnosis, it is of interest to assess survival probabilities
conditional on surviving up to a certain point [20, 21], and
not only in survival measured from diagnosis. For that
reason, it is of interest to present loss in expectation of life
conditional on surviving up to a certain time point. This is
of importance from the patient’s perspective, but also for
health care planning. Our results show that the loss in ex-
pectation of life decreases substantially within the first few



















1960 1970 1980 1990 2000 2010
Year of diagnosis
Females
Loss in expectation of life
Age 55 Age 65
Age 75 Age 85
Fig. 2 Temporal trends in the loss in expectation of life for colon cancer patients diagnosed in Sweden during 1961–2011
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to that seen in the general population.
A small but persistent sex difference in survival of colon
cancer patients has been observed in many studies, with
males having a worse prognosis [12, 16, 22, 23]. Neither the
reasons nor the impact of this difference is fully under-
stood. It may reflect differences in sub site distribution
[24–26], different anatomy with less efficient removal of
lymph nodes at surgery among male patients [27], comor-
bidity burden [28] or differences in the likelihood of early
diagnosis due to deep-rooted health care seeking behav-
iours [28, 29]. By estimating loss in expectation of life, we
have shown that among patients diagnosed with colon can-
cer in 2011, 945 life years could potentially have been saved
in Sweden if male patients had the same survival as female
patients. Quantifying the impact of survival differences be-
tween groups in this way could also be used for exploring
differences between socioeconomic groups, or between
countries. This has been the focus of a large number of
studies with some recent studies quantifying differences
as the number of avoidable deaths [30–35]. A disadvan-
tage of avoidable deaths is that the measure is highly
time-dependent, since deaths can only be postponed
and not avoided in the long run.
Another approach of comparing the life expectancy of
cancer patients to the life expectancy of the general
population is to estimate years of life lost (YLL) [36–38].
This is estimated by comparing the age at death of those
dying due to cancer and the expected age at death for
each individual or a pre-specified cut-off age (for ex-
ample mean age at death in the population). One of the
limitations with YLL is that its estimation relies onaccurate cause of death classification. Another limitation
is that this approach only includes patients that have
died due to cancer, irrespective of when they were diag-
nosed, and therefore it cannot be used for a specific
cohort of patients. Also, if a cut-off age is used, any dif-
ferences between groups that occur after the cut-off age
are ignored. The loss in expectation of life, on the other
hand, is an informative measure for understanding the
impact of cancer in the population, in a specific cohort
and on the life expectancy for an individual.
Strengths of our study included the use of population-
based data from the Swedish Cancer Register. The overall
completeness of the Swedish Cancer Register has been esti-
mated to 96 % [5]. Information on stage at diagnosis was
not available in this material, since the Swedish Cancer
Register did not collect stage information until 2003. Tem-
poral trends in life expectancy and loss in expectation of life
would certainly differ between stages. Survival for patients
with stage I colon cancer has been high for decades,
whereas survival for more advanced stages has improved
over time [14, 39]. It could also be of interest to include
information on treatment or local recurrence, but these
data have only been reported nationally since 2007, in
the Swedish Colorectal Cancer Registry. The only orga-
nized screening program in Sweden is in the Stockholm
region [40] and cannot have had an impact on the esti-
mated survival of the total study population. All inhabi-
tants in Stockholm between 60–69 years old are invited
to send in guaiac-based faecal occult blood tests. The
screening program started in 2008, including two birth
cohorts every year, so not all cohorts were included
when the current study stopped. In total 165 cases of
Table 3 Potential life years gained if sex differences in colon
cancer patient survival in Sweden could be eliminated, for
individual patients aged 55, 65, 75 and 85 and in the total
cohort diagnosed in 2011
Age Life years lost Life years lost using
female cancer
mortality rates
Extra years of life
using female cancer
mortality rates
Males Females Males Females Males Females
55 12.16 12.34 11.23 12.34 0.93 0
65 8.02 8.40 7.26 8.40 0.76 0
75 4.40 4.88 3.98 4.88 0.42 0
85 1.86 2.18 1.74 2.18 0.13 0
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Fig. 3 Loss in expectation of life conditional on time since diagnosis for colon cancer patients diagnosed in Sweden during 1961–2011
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screening between 2008 and 2011 [40] out of a total of
15,073 cases diagnosed between 2008 and 2011.Conclusion
In summary, assessing loss in expectation of life helps
improve the understanding of the impact of a diagnosis
of cancer and it is a good complement to the 5-year rela-
tive survival ratio. In this population-based study we
have demonstrated how summarizing colon cancer sur-
vival in terms of loss in expectation of life can be useful
in order to gain further insights of the impact of colon
cancer on both the individual and population level by
examining temporal trends, changes by time since diag-
nosis and quantifying differences between groups.
Andersson et al. BMC Cancer  (2015) 15:412 Page 9 of 10Additional file
Additional file 1: Statistical modeling and estimation.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TMLA, PWD, SE, PCL & ML participated in the design of the study. TMLA
carried out the statistical analysis and drafted the manuscript. All authors
participated in the interpretation of the data, revised the manuscript as well
as read and approved the final manuscript.
Acknowledgments
We thank Prof Olof Nyrén for valuable discussion and comments on an
earlier version of this manuscript. Part of this work was carried out while PCL
was granted study leave by the University of Leicester.
Author details
1Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
Box 281, SE-171 77 Stockholm, Sweden. 2Department of Molecular Medicine
and Surgery, Karolinska Institutet, Center of Surgical Gastroenterology,
Karolinska University Hospital, Stockholm, Sweden. 3Regional Cancer Centre,
Uppsala University Hospital, Uppsala, Sweden. 4Department of Health
Sciences, University of Leicester, Leicester, UK.
Received: 5 June 2014 Accepted: 6 May 2015
References
1. Dickman PW, Adami HO. Interpreting trends in cancer patient survival.
J Intern Med. 2006;260:103–17.
2. Hakama M, Hakulinen T. Estimating the expectation of life in cancer survival
studies with incomplete follow-up information. J Chronic Dis. 1977;30:585–97.
3. Andersson T, Dickman P, Eloranta S, Lambe M, Lambert P. Estimating the
loss in expectation of life due to cancer using flexible parametric survival
models. Stat Med. 2013;32(30):5286–300.
4. Lambert PC, Royston P. Further development of flexible parametric models
for survival analysis. Stata J. 2009;9:265–90.
5. Barlow L, Westergren K, Holmberg L, Talback M. The completeness of the
Swedish cancer register: a sample survey for year 1998. Acta Oncol.
2009;48:27–33.
6. Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for
relative survival, with application in coronary heart disease. Stat Med.
2007;26:5486–98.
7. Royston P, Parmar MK. Flexible parametric proportional-hazards and
proportional-odds models for censored survival data, with application to
prognostic modelling and estimation of treatment effects. Stat Med.
2002;21:2175–97.
8. Brenner H, Gefeller O. Deriving more up-to-date estimates of long-term
patient survival. J Clin Epidemiol. 1997;50:211–6.
9. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient
survival. Cancer. 1996;78:2004–10.
10. Statistics Sweden. The future population of Sweden 2012–2060.
Demographics report. 2012. p. 2.
11. Lee RD, Carter LR. Modeling and forecasting U.S. Mortality. J Am Stat Assoc.
1992;87:659–71.
12. Brenner H, Bouvier AM, Foschi R, Hackl M, Larsen IK, Lemmens V, et al.
Progress in colorectal cancer survival in Europe from the late 1980s to the
early 21st century: the EUROCARE study. Int J Cancer. 2012;131:1649–58.
13. Lemmens V, van Steenbergen L, Janssen-Heijnen M, Martijn H, Rutten H,
Coebergh JW. Trends in colorectal cancer in the south of the Netherlands
1975–2007: rectal cancer survival levels with colon cancer survival. Acta
Oncol. 2010;49:784–96.
14. van Steenbergen LN, Elferink MA, Krijnen P, Lemmens VE, Siesling S, Rutten HJ,
et al. Improved survival of colon cancer due to improved treatment and
detection: a nationwide population-based study in The Netherlands 1989–2006.
Ann Oncol. 2010;21:2206–12.15. Ostenfeld EB, Erichsen R, Iversen LH, Gandrup P, Norgaard M, Jacobsen J.
Survival of patients with colon and rectal cancer in central and northern
Denmark, 1998–2009. Clin Epidemiol. 2011;3 Suppl 1:27–34.
16. Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B. Improved
survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol.
2005;31:845–53.
17. McArdle CS, McKee RF, Finlay IG, Wotherspoon H, Hole DJ. Improvement
in survival following surgery for colorectal cancer. Br J Surg.
2005;92:1008–13.
18. Mitry E, Bouvier AM, Esteve J, Faivre J. Benefit of operative mortality
reduction on colorectal cancer survival. Br J Surg. 2002;89:1557–62.
19. Davila JA, Rabeneck L, Berger DH, El-Serag HB. Postoperative 30-day mortality
following surgical resection for colorectal cancer in veterans: changes in the right
direction. Dig Dis Sci. 2005;50:1722–8.
20. Merrill RM, Hunter BD. Conditional survival among cancer patients in the
United States. Oncologist. 2010;15:873–82.
21. Zamboni BA, Yothers G, Choi M, Fuller CD, Dignam JJ, Raich PC, et al.
Conditional survival and the choice of conditioning set for patients with
colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol.
2010;28:2544–8.
22. Eloranta S, Lambert PC, Cavalli-Bjorkman N, Andersson TM, Glimelius B,
Dickman PW. Does socioeconomic status influence the prospect of cure
from colon cancer–a population-based study in Sweden 1965–2000. Eur
J Cancer. 2010;46:2965–72.
23. Purim O, Gordon N, Brenner B. Cancer of the colon and rectum: potential
effects of sex-age interactions on incidence and outcome. Med Sci Monit.
2013;19:203–9.
24. DeCosse JJ, Ngoi SS, Jacobson JS, Cennerazzo WJ. Gender and colorectal
cancer. Eur J Cancer Prev. 1993;2:105–15.
25. Nawa T, Kato J, Kawamoto H, Okada H, Yamamoto H, Kohno H, et al.
Differences between right- and left-sided colon cancer in patient characteristics,
cancer morphology and histology. J Gastroenterol Hepatol. 2008;23:418–23.
26. Wong R. Proximal tumors are associated with greater mortality in colon
cancer. J Gen Intern Med. 2010;25:1157–63.
27. Nedrebo B, Soreide K, Nesbakken A, Eriksen M, Soreide J, Korner H. Risk
factors associated with poor lymph node harvest after colon cancer surgery
in a national cohort. Colorectal Dis. 2013;15:e301–8.
28. Oksuzyan A, Juel K, Vaupel JW, Christensen K. Men: good health and high
mortality. Sex differences in health and aging. Aging Clin Exp Res.
2008;20:91–102.
29. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour:
literature review. J Adv Nurs. 2005;49:616–23.
30. Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman MP. What if
cancer survival in Britain were the same as in Europe: how many deaths are
avoidable? Br J Cancer. 2009;101 Suppl 2:S115–24.
31. Pokhrel A, Martikainen P, Pukkala E, Rautalahti M, Seppa K, Hakulinen T.
Education, survival and avoidable deaths in cancer patients in Finland. Br
J Cancer. 2010;103:1109–14.
32. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, et al.
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and
the UK, 1995–2007 (the International Cancer Benchmarking Partnership):
an analysis of population-based cancer registry data. Lancet.
2011;377:127–38.
33. Morris EJ, Sandin F, Lambert PC, Bray F, Klint A, Linklater K, et al. A
population-based comparison of the survival of patients with colorectal
cancer in England, Norway and Sweden between 1996 and 2004. Gut.
2011;60:1087–93.
34. Lambert PC, Holmberg L, Sandin F, Bray F, Linklater KM, Purushotham A,
et al. Quantifying differences in breast cancer survival between England and
Norway. Cancer Epidemiol. 2011;35:526–33.
35. Ellis L, Coleman MP, Rachet B. How many deaths would be avoidable if
socioeconomic inequalities in cancer survival in England were eliminated?
A national population-based study, 1996–2006. Eur J Cancer. 2012;48:270–8.
36. Horm JW, Sondik EJ. Person-years of life lost due to cancer in the United
States, 1970 and 1984. Am J Public Health. 1989;79:1490–3.
37. Mettlin C. Trends in years of life lost to cancer: 1970 to 1985. CA Cancer
J Clin. 1989;39:33–9.
38. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost
(YLL) from cancer is an important measure of population burden–and
should be considered when allocating research funds. Br J Cancer.
2005;92:241–5.
Andersson et al. BMC Cancer  (2015) 15:412 Page 10 of 1039. Regionalt cancercentrum Norr. Nationell rapport, Koloncancer, 2011.
Available at: http://www.cancercentrum.se/Global/Diagnoser/kolorektal/
rapporter/colon2011.pdf. Assessed May 12, 2015.
40. Blom J, Kilpelainen S, Hultcrantz R, Tornberg S. Five-year experience of organized
colorectal cancer screening in a Swedish population–increased compliance with
age, female gender, and subsequent screening round. J Med Screen.
2014;21:144–50.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
